Copyright: ©Author(s) 2026.
World J Nephrol. Mar 25, 2026; 15(1): 115252
Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.115252
Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.115252
Table 2 Comparison of syndrome of inappropriate antidiuretic hormone, cerebral salt wasting, and reset osmostat
| Feature | SIADH | Cerebral salt wasting | Reset osmostat |
| Volume status | Euvolemic | Hypovolemic (true salt loss) | Euvolemic |
| Plasma sodium | Low | Low | Mildly low but stable |
| Urine sodium | > 30 mmol/L | > 30 mmol/L | Variable |
| Urine osmolality | > 100 mOsm/kg | > 100 mOsm/kg | Normal dilution capacity maintained |
| Serum uric acid | Low | Low | Normal or low-normal |
| Fractional excretion of uric acid | Elevated during hyponatremia (> 12%), normalizes after correction | Remains elevated after correction | Normal (< 11%) |
| Fractional excretion of sodium | > 0.5%-1% (inappropriately high for euvolemia) | > 1%-2% (due to true renal salt loss) | Normal or slightly increased |
| Fractional excretion of urea | > 55%-60% | > 60%-70% | Normal (< 35%) |
| Response to isotonic saline | No improvement or worsens hyponatremia | Improves serum sodium and volume | No major change |
| ADH secretion pattern | Inappropriate, independent of osmolality | Appropriate (secondary to hypovolemia) | Reset to a lower threshold |
| Volume markers (BUN, hematocrit) | Normal | Elevated (due to hypovolemia) | Normal |
| Treatment approach | Fluid restriction, salt tablets, urea, vaptans | Volume and salt repletion ± fludrocortisone | Usually none; avoid overcorrection |
| Typical setting | Pulmonary disorders, malignancy, CNS disease, drugs | CNS injury, subarachnoid hemorrhage, neurosurgery | Chronic illness, elderly, pregnancy, tuberculosis, carcinoma |
- Citation: Martínez-Sánchez FD, Gutierrez-Rosas LE, Barranco-Hernandez LH, Gonzalez-Alvarez G, Bastida-Castro LA, Rocha-Haro A, Barrientos-Cabrera G, Martínez-Cabrera CF, Balderas-Juarez J, Salinas-Ramirez MA, Hernandez-Castillo JL. Hyponatremia: Evolving diagnostics and emerging therapeutics in clinical practice. World J Nephrol 2026; 15(1): 115252
- URL: https://www.wjgnet.com/2220-6124/full/v15/i1/115252.htm
- DOI: https://dx.doi.org/10.5527/wjn.v15.i1.115252